For decades, Beckman Coulter Diagnostics has been a pioneer in industry-leading solutions that support a more sustainable future for our planet. At the heart of this mission is our commitment to promoting and preserving human health. Facing global diagnostic testing surges, economic pressures, and a need for environmentally conscious practices, Beckman Coulter offers transformative solutions that empower laboratories to meet these demands.
By enhancing the speed, range, and precision of our diagnostic equipment, we empower medical laboratories to deliver reliable results faster, enabling quicker, often life-saving medical interventions. This work is crucial as we face rising public health crises worldwide, and we’re dedicated to innovating solutions that support a healthier population and a more sustainable future.
As a Danaher operating company, we share a commitment to sustainable practices that drive advancement in the diagnostics industry. Together, we prioritize creating industry-leading products that help our customers tackle critical healthcare challenges, improving quality of life globally.
Advancing Diagnostic Speed and Accuracy with the DxI 9000 Immunoassay Analyzer
Developed by Beckman Coulter, the DxI 9000 Immunoassay Analyzer is an award-winning product that sets a new standard in diagnostics with its impressive immunoassay testing capabilities. Delivering an industry-leading throughput of up to 450 tests per hour, the DxI 9000 Immunoassay Analyzer enhances lab productivity delivering rapid, high-quality diagnostic results.
This high-sensitivity immunoassay analyzer allows laboratories to deliver results with heightened sensitivity at lower sample volumes and in high-throughput settings. The DxI 9000’s Immunoassay Analyzer improved signal-to-noise ratio reduces light interference across various measurement methods, and it can detect concentration levels that equate to a single teaspoon of sugar in 100,000 Olympic-sized swimming pools. The true strengths of the DxI 9000 Immunoassay Analyzer include:
- Faster Results: Essential for many life-saving treatments.
- Expanded Diagnostic Range: Enables screening for a broader range of conditions and markers.
- Improved Substrate: Designed for faster, more sensitive detection.
- Advanced Pipetting: Providing more precise sample management.
- Improved Temperature Controls: Improving reaction control for each target analyte.
These advancements in immunoassay detection and analyzer performance are having a positive impact in hospitals and laboratories across the globe, improving the health of people each day. Let’s dive into three key areas where the DxI 9000 Immunoassay Analyzer is transforming healthcare and helping address critical health crises at an early stage.
When Seconds Matter: Elevating Cardiology Diagnostics
Achieving better patient outcomes hinges on quickly identifying a therapeutic option. When a patient arrives in the emergency department with chest pain, the team collaborates closely with the clinical laboratory to evaluate whether a cardiac event is occurring. The DxI 9000 Immunoassay Analyzer provides a comprehensive cardiology panel, but its speed and accuracy are the true differentiators. Reducing test time by even five minutes can facilitate faster diagnosis and significantly impact the management of acute myocardial infarctions, allowing life-saving interventions to take place when seconds count. Effective management of cardiovascular diseases depends on timely, informed decisions, and the DxI 9000 Immunoassay Analyzer enables just that.
Advancing HIV Detection
Since its appearance in the 1980s, HIV has infected 85.6 million people and killed over 40 million people.
[1] The first generation of HIV antibody tests could not detect the virus and only detected the presence of antibodies against the virus, which typically appear 6-12 weeks after infection. These early tests were also fraught with false positives and confirmatory testing was needed
[2].
The DxI 9000 Immunoassay Analyzer introduces the 4th generation of HIV testing, which detects both the HIV-1 p24 antigen and IgM and IgG antibodies. This dual detection capability enables earlier diagnosis, allowing patients to begin treatment sooner. The test’s heightened sensitivity meets the growing demand for accurate HIV testing.
Innovating for a Healthier Future
At Beckman Coulter, we’re dedicated to improving patient care worldwide because we believe a sustainable future requires a healthy population. With 90 years of diagnostic innovation, a legacy of workflow efficiency, and unmatched reliability and scalability, we are advancing the future of diagnostics. Today, all our solutions across the globe conduct over a million tests per hour, impacting more than 1.2 billion patients each year, while our biomarkers unlock unprecedented clinical insights, providing meaningful, actionable data.
[1] WHO. HIV. THE GLOBAL HEALTH OBSERVATORY. 2024. Accessed March 22, 2024. https://www.who.int/data/gho/data/themes/hiv-aids
[2] Alexander TS. Human immunodeficiency virus diagnostic testing: 30 years of evolution. Clin Vaccine Immunol. 2016;23(4):249-253. doi:10.1128/CVI.00053-16
#2024-13752
English
